These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 32399253)
21. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047 [TBL] [Abstract][Full Text] [Related]
22. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944 [TBL] [Abstract][Full Text] [Related]
24. Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blind, placebo-controlled trial. Salmon J; Wallace DJ; Rus V; Cox A; Dykas C; Williams B; Ding Y; Hals PA; Johnsen L; Lipsky PE Lupus Sci Med; 2024 Jul; 11(2):. PubMed ID: 39009356 [TBL] [Abstract][Full Text] [Related]
25. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114 [TBL] [Abstract][Full Text] [Related]
26. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications. Philbin M; Niewoehner J; Wan GJ Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550 [TBL] [Abstract][Full Text] [Related]
27. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review. Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646 [TBL] [Abstract][Full Text] [Related]
28. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488 [TBL] [Abstract][Full Text] [Related]
29. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918 [TBL] [Abstract][Full Text] [Related]
30. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial. Sun F; Huang W; Chen J; Zhao L; Zhang D; Wang X; Wan W; Dai SM; Chen S; Li T; Ye S Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35105722 [TBL] [Abstract][Full Text] [Related]
31. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus. Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112 [TBL] [Abstract][Full Text] [Related]
32. Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development. Goteti K; French J; Garcia R; Li Y; Casset-Semanaz F; Aydemir A; Townsend R; Mateo CV; Studham M; Guenther O; Kao A; Gastonguay M; Girard P; Benincosa L; Venkatakrishnan K CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):180-195. PubMed ID: 36350330 [TBL] [Abstract][Full Text] [Related]
33. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931 [TBL] [Abstract][Full Text] [Related]
34. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod. Petri MA; Martin RS; Scheinberg MA; Furie RA Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505 [TBL] [Abstract][Full Text] [Related]
35. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839 [TBL] [Abstract][Full Text] [Related]
36. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. van Vollenhoven RF; Stohl W; Furie RA; Fox NL; Groark JG; Bass D; Kurtinecz M; Pobiner BF; Eastman WJ; Gonzalez-Rivera T; Gordon D Lupus Sci Med; 2018; 5(1):e000288. PubMed ID: 30588323 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507 [TBL] [Abstract][Full Text] [Related]
38. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807 [TBL] [Abstract][Full Text] [Related]